Histo-morphological assessment of the oral effect of gadolinium nanocomposite on kidneys and liver of white rats

Introduction. The prospect of using gadolinium nanoparticles to achieve high-contrast images when performing MRI with a significantly lower amount of the injected substance dictates the need for its comprehensive study. The high efficiency of nanoparticles can be achieved only due to an effective nanostabilizing matrix, a high–molecular compound of arabinogalactan isolated from Siberian larch wood.

Materials and methods. Gadolinium nanocomposite encapsulated in a natural polymer matrix of arabinogalactan was administered per os for 10 days to adult mature male white rats (seventy two individuals) at a dose of 500 µg/kg body weight and 5000 µg/kg body weight, respectively. The examination took place in 2 stages – immediately after the end of the seed (early period) and 6 months after the end of exposure (remote period). A set of methods was used to assess the structural and functional state of the kidneys and liver, as well as determine the concentration of gadolinium in the above-mentioned organs.

Results. The structural and functional features of the gadolinium nanocomposite effect on kidney tissue were expressed in a change in the area of the Shumlyansky–Bowman capsule, both in the early and in the long-term post-exposure period, however, these changes fit into the parameters of the physiological norm for this organ, while it was proved that the nanocomposite is able to penetrate into the liver and kidney tissue, remaining there in the remote post-contact period.

Limitations. The use of one type of animal, a limited number of techniques used.

Conclusion. The gadolinium nanoparticles, due to their specified physico-chemical characteristics and the almost complete absence of toxicity to target organs (kidneys, liver), are promising therapeutic and diagnostic drugs, which can later be used to create new-generation diagnostic drugs.

Compliance with ethical standards. The work was carried out in accordance with the protocol of experimental research, the principles set out in the European Convention for the Protection of Vertebrate Animals Used for Experiments or Other Scientific Purposes ETS No. 123, GOST 33215–2014 “Guidelines for the care and care of laboratory animals. Rules of equipment of premises and organization of procedures”, Recommendations for euthanasia of experimental animals: Part 1, Part 2. Permission was obtained from the Local Ethics Committee to conduct research (Protocol No. 8 dated 12/15/2023).

Contribution:
Novikov M.A. – concept and design of research, data processing, editing, writing;
Titov E.A. – concept and design of research editing;
Pankova A.A. – collection of material and data processing;
Lisetskaya L.G. – sample preparation of materials for concentration determination, recalculation of primary quantitative data;
Sosedova L.M. – concept and research design, editing, and writing.
All authors are responsible for the integrity of all parts of the manuscript and approval of the manuscript final version.

Using AI. To search for additional sources of literature, DeepSeek V4 artificial intelligence-based software was used (date of use – 03/19/2026).

Conflict of interest. The authors declare no conflict of interest.

Funding. The study was carried out within the framework of the state assignment of the East Siberian Institute of Medical and Environmental Research.

Received: April 13, 2026 / Accepted: July 1, 2026 / Published: October 20, 2026

1. Kermanizadeh A., Powell L.G., Stone V. A review of hepatic nanotoxicology – summation of recent findings and considerations for the next generation of study designs. J. Toxicol. Environ. Health B Crit. Rev. 2020; 23(4): 137–76. https://doi.org/10.1080/10937404.2020.1751756 https://elibrary.ru/gqyicc

2. Domingues C., Santos A., Alvarez-Lorenzo C., Concheiro A., Jarak I., Veiga F., et al. where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology. ACS Nano. 2022; 16(7): 9994–10041. https://doi.org/10.1021/acsnano.2c00128 https://elibrary.ru/vfsgbe

3. Yang W., Wang L., Mettenbrink E.M., DeAngelis P.L., Wilhelm S. Nanoparticle toxicology. Annu. Rev. Pharmacol. Toxicol. 2021; 61: 269–89. https://doi.org/10.1146/annurev-pharmtox-032320-110338 https://elibrary.ru/utwver

4. Krug H.F., Nau K. Editorial: Methods and protocols in nanotoxicology. Front. Toxicol. 2022; 4: 1093765. https://doi.org/10.3389/ftox.2022.1093765 https://elibrary.ru/yfbmmw

5. Johari S.A., Yu I.J., Valsami-Jones E. Editorial: Methods and protocols in nanotoxicology: volume II. Front. Toxicol. 2025; 6: 1532023. https://doi.org/10.3389/ftox.2024.1532023 https://elibrary.ru/tfipgj

6. Ho S.L., Yue H., Tegafaw T., Ahmad M.Y., Liu S., Nam S.W., et al. Gadolinium Neutron Capture Therapy (GdNCT) agents from molecular to nano: current status and perspectives. ACS Omega. 2022; 7(3): 2533–53. https://doi.org/10.1021/acsomega.1c06603 https://elibrary.ru/xhgwmu

7. Siedek F., Muehe A.M., Theruvath A.J., Avedian R., Pribnow A., Spunt S.L., et al. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. Eur. Radiol. 2020; 30(3): 1790–803. https://doi.org/10.1007/s00330-019-06569-y https://elibrary.ru/himsdk

8. Nitta N., Takakusagi Y., Kokuryo D., Shibata S., Tomita A., Higashi T., et al. Intratumoral evaluation of 3D microvasculature and nanoparticle distribution using a gadolinium-dendron modified nano-liposomal contrast agent with magnetic resonance micro-imaging. Nanomedicine. 2018; 14(4): 1315–24. https://doi.org/10.1016/j.nano.2018.03.006

9. Rukavishnikov V.S., Sosedova L.M., Vokina V.A., Titov E.A., Novikov M.A., Yakimova N.L. Assessment of neurotoxicity of nanometals encapsulated on arabinogalactan matrix. Meditsina truda i promyshlennaya ekologiya. 2017; 57(10): 25–9. https://elibrary.ru/ztuvhr (in Russian)

10. Sukhov B.G., Konkova T.V., Titova Yu.Yu., Ivanov A.V. Nanocomposites based on gadolinium-containing compounds for the diagnosis, therapy, and theranostics of brain cancer and methods for their production. Patent RF No. 2778928; 2022. https://elibrary.ru/mfrnvh (in Russian)

11. Rukavishnikov V.S., Novikov M.A., Titov E.A., Sosedova L.M. Estimation of toxic properties of nanocomposites containing nanoparticles of bismuth, gadolinium, and silver. Тrace Elem. Electroly. 2018; 35: 203–6. https://doi.org/10.5414/TEX0155408 https://elibrary.ru/yokibn

12. Avtandilov G.G. Morphometry in Pathology [Morfometriya v patologii]. Moscow: Meditsina; 1973. (in Russian)

13. Ergun I., Keven K., Uruc I., Ekmekci Y., Canbakan B., Erden I., et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol. Dial. Transpl. 2006; 21(3): 697–700. https://doi.org/10.1093/ndt/gfi304 https://elibrary.ru/ixqfah

14. Briguori C., Colombo A., Airoldi F., Melzi G., Michev I., Carlino M., et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter. Cardiovasc. Interv. 2006; 67(2): 175–80. https://doi.org/10.1002/ccd.20592

15. Elmstahl B., Leander P., Grant D., Doughty R.W., Chai C.M., Bjork J., et al. Histomorphological changes after renal X-ray arteriography using iodine and gadolinium contrast media in an ischemic porcine model. Acta Radiol. 2007; 48(10): 1109–19. https://doi.org/10.1080/02841850701663442

16. Takahashi E.A., Kallmes D.F., Mara K.C., Harmsen W.S., Misra S. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. Diagn. Interv. Radiol. 2018; 24(6): 378–84. https://doi.org/10.5152/dir.2018.18172

17. Martino F., Amici G., Rosner M., Ronco C., Novara G. Gadolinium-based contrast media nephrotoxicity in kidney impairment: the physio-pathological conditions for the perfect murder. J. Clin. Med. 2021; 10(2): 271. https://doi.org/10.3390/jcm10020271 https://elibrary.ru/akirbh

18. Rogosnitzky M., Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29(3): 365–76. https://doi.org/10.1007/s10534-016-9931-7 https://elibrary.ru/ckqknq

19. De Aguero J., Howard T., Kusewitt D., Brearley A., Ali A. M., Degnan J.H., et al. The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from magnetic resonance imaging contrast agent exposure. Sci. Rep. 2023; 13(1): 2025. https://doi.org/10.1038/s41598-023-28666-1 https://elibrary.ru/sbgves

20. Tyutrina V.A., Andreeva E.S., Vokina V.A., Titov E.A., Novikov M.A., Sosedova L.M. In vivo and in vitro analysis of toxicity of a prospective magnetic resonance contrast agent based on arabinogalactan and gadolinium nanocomposite. Bulletin of Experimental Biology and Medicine. 2023; 17(5): 695–9. https://doi.org/10.1007/s10517-023-05928-6 https://elibrary.ru/qjftao

21. Korolenko T.A., Dergunova M.A., Alekseenko T.V., Zhanaeva S.Y., Filyushina E.E., Filatova T.G. Intralysosomal accumulation of gadolinium and lysosomal damage during selective depression of liver macrophages in vivo. Bull. Exp. Biol. Med. 2006; 142(4): 391–4. https://doi.org/10.1007/s10517-006-0373-z https://elibrary.ru/ljpdlf